Christopher Jewell

Christopher M. Jewell’s experience spans over 20 years, including as founder of multiple companies, Chief Scientific Officer at Cartesian Therapeutics, a consultant with the Boston Consulting Group (New York), an advisor to dozens of start-ups and large pharma companies, and as Institute Professor of Translational Engineering at the University of Maryland. He is a recognized KOL in immunotherapy and vaccine innovation, cell therapy, nucleic acid delivery, and biomaterials. His work at the interface of immunology, bioengineering, and nanotechnology has catalyzed new immunotherapy technologies in autoimmunity and oncology. Dr. Jewell’s research has been supported by $33M+ in non-dilutive funding and resulted in 150 patents and papers in top journals, including Nature, Nature Biotechnology, and Science Translational Medicine. He is an elected Fellow of numerous societies and has received over 50 professional honors, including being honored by the White House with the Presidential Early Career Award for Scientists and Engineers (PECASE)–the United States’ highest honor to such scientists. Dr. Jewell carried out his postdoctoral training as a Ragon Fellow with Dr. Darrell Irvine at MIT and as a Visiting Scientist at Harvard with Dr. Dan Barouch (Div. of Vaccine Research). He graduated from Lehigh University (high honors), earning dual degrees in Chemical Engineering and Molecular Biology, then received his PhD in Chemical Engineering from the University of Wisconsin